Phase 3 N=139 Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
Chemotherapy-induced Diarrhea
Primary: Percentage of Participants Developing Diarrhea (Grade 1 to 4) — 76.1; 78.9 Percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=424 A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors
Leukemia, Lymphoblastic, Acute · Osteoporosis
Primary: Effect of Taking Calcium and Vitamin D Supplements on Bone Mineral Density (BMD) — -0.95; -0.97; -0.87; -1.04 Z-Score — p=0.86
Phase 3 N=723 Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Kidney Neoplasms
Primary: Progression-Free Survival (PFS) — 6.7; 4.7 Months — p=<0.0001
Phase 3 N=5,752 Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical…
Phase 3 N=63 Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)
Primary Immune Deficiency Disorders (PIDD)
Primary: Rate of Serious Bacterial Infections (SBIs) Per Person-year on Treatment — 0.035 SBIs Per Total Person-Years
Phase 3 N=130 Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching — 0.4; 1.9; 0.4; 0.5 Units on a scale
Phase 3 N=534 Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
Non Small Cell Lung Cancer · Lung Cancer
Primary: Progression-Free Survival (PFS) in the Overall Population — 17.6; 11.9 weeks
Phase 3 N=123 Phase IIIB Switching From Intravenous to Subcutaneous Study
Arthritis, Rheumatoid
Primary: Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Treatment-related Adverse Events…
Phase 3 N=569 Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults
HIV Infections
Primary: Treatment Response at Week 48 — 126; 124; 250; 126 Patients — p=0.684
Phase 3 N=440 Vitamin K Supplementation in Post-Menopausal Osteopenia
Post-Menopausal Osteoporosis · Post-Menopausal Osteopenia
Primary: Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms. — -1.28; -1.22 percentage change in BMD — p=<0.05
Phase 3 N=924 ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
Non-Small-Cell Lung Carcinoma
Primary: Overall Survival (OS) — 8.5; 7.8 Months
Phase 3 N=107 Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Ocular Itching — 0.5; 1.9; 0.6; 0.8 Units on a scale
Phase 3 N=331 An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Thyroid Cancer
Primary: Progression-Free Survival(PFS) — 30.5; 19.2 Months
Phase 3 N=336 Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17
ADHD
Primary: Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 7 Weeks — -24.3; -18.7; -5.7 Scores on a…
Phase 3 N=238 Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose
Infections, Streptococcal
Primary: Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes. — 0.48; 0.35; 0.56; 0.48 µg/mL